Reiffen M, Eberlein W, Müller P, Psiorz M, Noll K, Heider J, Lillie C, Kobinger W, Luger P
Department of Chemical Research, Ressort Chemische Forschung, Biberach, West Germany.
J Med Chem. 1990 May;33(5):1496-504. doi: 10.1021/jm00167a033.
Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic alpha-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or beta-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibitors. The prototype falipamil (2) has been submitted to further optimization mainly by manipulation of the phthalmidine moiety. This has resulted in a second generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepinone ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.
通过用各种杂环系统取代亲脂性的α-异丙基乙腈部分对钙拮抗剂维拉帕米(1)进行结构修饰,已产生了一类新的心血管化合物,其特征在于具有特定的心动过缓活性。这些药物可降低心率,但不与经典的钙通道或β-肾上腺素能受体结合,而是与窦房结的结构特异性相互作用。因此,它们也被称为窦房结抑制剂。原型法利帕米(2)主要通过对酞咪部分进行操作而进行了进一步优化。这产生了第二代具有更高效力、选择性和更长作用持续时间的特异性心动过缓药物,以苯并氮杂䓬酮衍生物UL-FS 49(4)为代表。这类新型化合物的构效关系表明,活性对芳环的取代模式、中心氮原子的性质以及连接烷基链的长度有显著依赖性。苯并氮杂䓬酮环对心动过缓活性的关键作用可以通过其对整体分子构象的特殊影响得到最好的解释。